Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system

AIM： To determine the role of Fas/Fas ligand （FasL） in the immune escape of colon cancer cells. METHODS： Immunohistochemistry was used to observe the expression of Fas and FasL in the tissues of colon cancer patients. In situ hybridization was used to detect the localization of FasL mRNA expression in cancer tissues. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling （TUNEL） assay and CD45 staining were performed to detect the apoptosis of tumor-infiltrating lymphocytes （TILs）. Co-culture assays of colon cancer cells （SW480） and Jurkat cells （Fas-sensitive cells） were performed to observe the counterattack of colon cancer cells to lymphocytes. RESULTS： Of 53 cases of colon carcinomas, 23 cases （43.4%） expressed Fas which was significantly lower as compared to the normal colonic mucosa （73.3%, P〈0.01）, and 45 cases （84.9%） of colon carcinomas expressed FasL, whereas only two cases （3.75%） in normal mucosa expressed FasL. FasL expression in the colon cancer cells was found to be associated with increased cell death of TIEs. The apoptotic rate of TIL in the FasL-positive staining regions of tumor cells was significantly higher than that in the FasL-negative staining region （54.84±2.79% vs 25.73±1.98%, P〈0.01）. The co-culture of SW480 cells and Jurkat cells confirmed the function of FasL on the SW480 cells. The apoptotic rates of Jurkat cells were found to be related with the amount of SW480 cells. CONCLUSION： Colon cancer cells can escape the immune surveillance and killing via decreasing Fas expression, and can counterattack the immune system via increasing FasL expression. Fas/FasL can serve as potential targets for effective antitumor therapy.